Monsoon Communications is a premium investor and public relations firm, adding shareholder value to small and mid-cap companies.
Melbourne, Australia
Joined June 2012
- Tweets682
- Following754
- Followers408
- Likes119
Monsoon Communications retweeted
CLINUVEL was pleased to present at the #TwilightInvestorBriefing hosted by @MonsoonComms in Melbourne on 3 March 2026, focused on dividend paying companies. CFO Peter Vaughan and Head of Australian Operations & Investor Relations Malcolm Bull told CLINUVEL’s story to the investment community, highlighting the journey to profitability, now maintained for 9 1/2 years, and the payment of dividends for 8 consecutive years.
There was strong interest in the Company’s results for the half year to December 2025 and ongoing expansion to assist new patient populations, particularly vitiligo.
Thank you to Monsoon Communications and FB Rice for hosting the event and enabling us to highlight the determination and persistence needed in the biotech sector to achieve and maintain profitability and dividends.
#Dermatology #BioTech #Pharma #Vitiligo #EPP #SkinHealth #Science #ASX #Peptides $CUV.AX $CLVLY
Monsoon Communications retweeted
Biotron CEO Dr Michelle Miller is joining @ausbiztv to discuss new HBV data. BIT-HBV001 shows strong in-vivo activity, outperforms the global standard of care, Tenofovir, in vitro. 🎥 Watch LIVE NOW: ausbiz.com.au/
Monsoon Communications retweeted
Biotron (ASX:BIT) reports major progress on its HBV program.
BIT-HBV001 shows strong antiviral activity in two mouse models, broad inhibition across all key HBV markers incl. cccDNA, and synergy with Tenofovir. New patent filed.
Full update ⬇️
announcements.asx.com.au/asx…
Monsoon Communications retweeted
Biotron Limited’s Managing Director, Dr Michelle Miller, and Sedarex Limited Director, Graeme-David Wald, shared an update on the Sedarex acquisition and introduce its next-generation general anaesthetic technology, SedRx™.
🎥 Watch now: youtu.be/_ux5Aex7KwA
Monsoon Communications retweeted
Biotron outlines the next 12 months of milestones — from advancing its Hepatitis B program to SedRx’s regulatory and efficacy goals that open new blue-sky potential for investors.
🔗 Investor Inquiry: [email protected]
📺 Full Interview: youtu.be/hrmITqMbCb0
#Biotech #Sedarex
Monsoon Communications retweeted
Biotron’s Sedarex acquisition signals a move beyond antivirals — introducing a near-term, revenue-ready asset while de-risking the portfolio for investors.
🔗 Investor Inquiry: [email protected]
📺 Full Interview: youtu.be/hrmITqMbCb0
#Biotech #Sedarex
Monsoon Communications retweeted
Biotron’s CEO Dr Michelle Miller shares how SedRx™ offers superior post-op cognitive outcomes compared with propofol, the global standard — one of the key reasons behind the strategic acquisition.
🔗 Investor Inquiry: [email protected]
📺 Full Interview: youtu.be/hrmITqMbCb0
#Biotech #Sedarex
Monsoon Communications retweeted
CEO Dr Michelle Miller on how the Sedarex acquisition and $2.5M raise position Biotron for its next growth phase, expanding into anaesthesia and neuroscience.
🔗 Investor Inquiry: [email protected]
📺 Full Interview: youtu.be/hrmITqMbCb0?si=DoEm…
#Biotech #Sedarex
Monsoon Communications retweeted
Thank you @StockheadAU for covering Biotron’s acquisition of Sedarex, expanding beyond antivirals into anaesthesia & neuroscience with SedRx™, a next-gen anaesthetic showing improved safety & cognitive outcomes.
🔗 Read the full story: bit.ly/biotron-goes-all-numb…
Monsoon Communications retweeted
Prominent investment manager Tony Locantro chose Dimerix as one of his Top 5 biotech stocks for 2023. Find out why and his other picks in the article below:
Tony Locantro, small-cap biotech and mining legend, recently shared his top stock picks for 2023. Speculative but potentially transformative, and bigger than a Guns 'N Roses concert. Read all of @LocantroTony 's tips here: bit.ly/3WwGifm
Monsoon Communications retweeted
Pre-clinical studies have shown that monepantel can slow disease progression in MND models by clearing harmful materials in a motor neuron that stick together and make them unwell. The upcoming Phase 1 trial aims to advance monepantel as a potential therapeutic for MND
@FightMND
Monsoon Communications retweeted
It’s great to be back attending conferences & hearing from others in the #biotech space. CEO & MD Nina Webster presented at the 16th Bioshares Biotech Summit on what’s happening in the global #kidney space & why DXB is positioned to deliver its #FSGS goals bit.ly/3NbuviG
Monsoon Communications retweeted
Dimerix is pleased to announce it has reached another significant milestone for its DMX-200 Phase 3 focal segmental glomerulosclerosis clinical trial. The company has received FDA #IND approval, allowing the company to begin patient recruitment in the US: bit.ly/3skydOR
Monsoon Communications retweeted
Bio-Gene CEO @richjagger appeared on Ticker News @tickerNEWSco recently discussing sustainable consumer trends, latest developments and upcoming milestones for the company.
🎥 Watch the interview below: ow.ly/hX4950GK0Pg
$BGT #NovelSaferBetter
Monsoon Communications retweeted
Interested in exploring the latest trends at the forefront of medical innovation across #biotech and #pharmaceuticals? Don't forget to register for our upcoming webinar with our partners @MonsoonComms
To register, click here: educate.link/biotech
$AVH $BIT $AVE $PXS
Monsoon Communications retweeted
Australia's vaccination efforts need to go hand-in-hand with #covid19 therapy drugs. DMX-200, as part of the CLARITY2.0 study, has the potential to prevent intensive hospital care by easing early-stage respiratory symptoms: ab.co/3kOdb8t
@MTPConnect_AUS
Monsoon Communications retweeted
New COVID study data published in Nature Genetics in Medicine shows further evidence that the CCR2 gene causes increased COVID-19 severity. Our lead candidate DMX-200 is the only CCR2 blocking drug actively in development for #COVID19: go.nature.com/3yzmKM7
Monsoon Communications retweeted
PharmAust flags good news on key stability test for Monepantel treatment
stockhead.com.au/health/phar…
Monsoon Communications retweeted
Looking forward to pitching next week at @AusBiotech's launch of #BiotechPitch #Investment #CellTherapy #immunology
Register now: Hear investment opportunities from Australia's innovative #regenmed & #celltherapy companies @Chimeric @cynatastemcells @CarinaBiotech @PTX_AUS + from Mitchell Asset Management #BiotechPitch ausbiotech.eventsair.com/bio…
